A detailed history of Jump Financial, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Jump Financial, LLC holds 155,767 shares of ARWR stock, worth $3.47 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
155,767
Previous 92,876 67.72%
Holding current value
$3.47 Million
Previous $2.41 Million 24.95%
% of portfolio
0.07%
Previous 0.05%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.36 - $29.54 $1.22 Million - $1.86 Million
62,891 Added 67.72%
155,767 $3.02 Million
Q2 2024

Aug 14, 2024

BUY
$21.87 - $28.24 $1.34 Million - $1.73 Million
61,174 Added 192.97%
92,876 $2.41 Million
Q1 2024

May 13, 2024

SELL
$27.21 - $39.48 $30,584 - $44,375
-1,124 Reduced 3.42%
31,702 $906,000
Q4 2023

Oct 21, 2024

SELL
$21.2 - $31.03 $1.73 Million - $2.53 Million
-81,607 Reduced 71.31%
32,826 $1 Million
Q4 2023

Feb 07, 2024

SELL
$21.2 - $31.03 $1.73 Million - $2.53 Million
-81,607 Reduced 71.31%
32,826 $1 Million
Q3 2023

Oct 21, 2024

BUY
$26.2 - $36.08 $2.27 Million - $3.13 Million
86,807 Added 314.22%
114,433 $3.07 Million
Q3 2023

Nov 07, 2023

BUY
$26.2 - $36.08 $2.27 Million - $3.13 Million
86,807 Added 314.22%
114,433 $3.07 Million
Q2 2023

Oct 21, 2024

BUY
$25.16 - $41.38 $117,748 - $193,658
4,680 Added 20.4%
27,626 $985,000
Q2 2023

Aug 07, 2023

BUY
$25.16 - $41.38 $117,748 - $193,658
4,680 Added 20.4%
27,626 $985,000
Q1 2023

Oct 21, 2024

SELL
$23.68 - $38.51 $1.66 Million - $2.69 Million
-69,930 Reduced 75.29%
22,946 $582,000
Q1 2023

May 03, 2023

BUY
$23.68 - $38.51 $543,361 - $883,650
22,946 New
22,946 $582,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.36B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.